Short Interest in Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Increases By 494.7%

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) was the target of a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 514,441 shares, a growth of 494.7% from the May 14th total of 86,503 shares. Based on an average daily trading volume, of 335,136 shares, the short-interest ratio is presently 1.5 days. Currently, 1.1% of the shares of the company are sold short.

Odyssey Therapeutics Stock Performance

Shares of Odyssey Therapeutics stock traded up $0.56 during trading on Wednesday, hitting $17.65. 31,348 shares of the company were exchanged, compared to its average volume of 311,274. Odyssey Therapeutics has a fifty-two week low of $15.35 and a fifty-two week high of $20.30.

Wall Street Analyst Weigh In

ODTX has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating for the company. TD Cowen initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued a “buy” rating for the company. Wedbush initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective for the company. Oppenheimer initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Zacks Research upgraded shares of Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Odyssey Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Insider Buying and Selling at Odyssey Therapeutics

In other news, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $18.00, for a total value of $32,040.00. Following the completion of the sale, the insider owned 440,981 shares in the company, valued at approximately $7,937,658. This trade represents a 0.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dimension Capital Ii, L.P. bought 1,111,111 shares of Odyssey Therapeutics stock in a transaction dated Friday, May 8th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the purchase, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. This trade represents a 50.00% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 4,183,777 shares of company stock valued at $75,319,986.